Gene engineering in mouse embryos or embryonic stem cells (mESCs) allows for the study of the function of a given protein. Proteins are the workhorses of the cell and often consist of multiple functional domains, which can be influenced by posttranslational modifications. The depletion of the entire protein in conditional or constitutive knock-out (KO) mice does not take into account this functional diversity and regulation. An mESC line and a derived mouse model, in which a docking site for FLPe recombination-mediated cassette exchange (RMCE) was inserted within the ROSA26 (R26) locus, was previously reported. Here, we report on a structure-function approach that allows for molecular dissection of the different functionalities of a multidomain protein. To this end, RMCE-compatible mice must be crossed with KO mice and then RMCEcompatible KO mESCs must be isolated. Next, a panel of putative rescue constructs can be introduced into the R26 locus via RMCE targeting. The candidate rescue cDNAs can be easily inserted between RMCE sites of the targeting vector using recombination cloning. Next, KO mESCs are transfected with the targeting vector in combination with an FLPe recombinase expression plasmid. RMCE reactivates the promoter-less neomycin-resistance gene in the ROSA26 docking sites and allows for the selection of the correct targeting event. In this way, high targeting efficiencies close to 100% are obtained, allowing for insertion of multiple putative rescue constructs in a semi-high throughput manner. Finally, a multitude of R26-driven rescue constructs can be tested for their ability to rescue the phenotype that was observed in parental KO mESCs. We present a proof-of-principle structure-function study in p120 catenin (p120ctn) KO mESCs using endoderm differentiation in embryoid bodies (EBs) as the phenotypic readout. This approach enables the identification of important domains, putative downstream pathways, and diseaserelevant point mutations that underlie KO phenotypes for a given protein.
Introduction
It is estimated that mammalian genomes contain about 20,000 protein-coding genes. Alternative splicing and posttranslational modifications further increase the protein repertoire. Proteins have a modular structure 1 and often contain multiple interaction domains, which allow their recruitment into different protein complexes and their participation in multiple cellular processes 2 . One example is the multi-functional protein called p120ctn. p120ctn is encoded by the Ctnnd1 gene and consists of a large central armadillo repeat domain flanked by an N-terminal and a C-terminal region. The armadillo domain of p120ctn binds to a highly conserved juxtamembrane domain of classical cadherins, which are involved in cell-cell adhesion, but it also binds to the transcriptional repressor Kaiso. The N-terminal domain of p120ctn interacts with different kinases, phosphatases, small RhoGTPases, and microtubule-associated proteins Gene targeting in mESCs enables the study of the function of a protein through the genetic deletion of the corresponding gene and has widely contributed to the identification of developmentally important and disease-relevant genes and pathways. This breakthrough in reverse genetics was the result of advances in the fields of mESC isolation and gene targeting due to homologous recombination 5 . Homologous recombination is a process in which DNA fragments are exchanged between two similar or identical nucleic moieties after double-stranded (ds) DNA breaks. Normally, HR is inefficient because dsDNA breaks are infrequent. Recently, the efficiency of homology-directed gene targeting could be increased using site-specific nucleases 6, 7 , but unfortunately, these are prone to off-target effects 8 . A more reliable technique to enable gene targeting is RMCE, which is based on site-specific recombination systems such as Cre/loxP or FLPe/Frt. LoxP and Frt sequence are found in bacteriophage P1 and Saccharomyces cerevisiae, respectively, and consist of 34 bp, including an asymmetric 8 bp sequence that determines the orientation of the site. On the other hand, the orientation of, for instance, two loxP sites within a DNA stretch will determine whether the floxed DNA becomes excised or inversed upon Cre-mediated recombination 9 . Moreover, Cre can also induce a translocation if two sites are located on different chromosomes. RMCE takes advantage of heterospecific recombination sites that do not cross-react and that are embedded in a genomic locus. In the presence of a donor plasmid that contains a DNA fragment flanked by the same heterospecific sites, the recombinase will insert this DNA fragment into the RMCE-compatible genomic locus because of double-simultaneous translocation (Figure 1) . Here, only correctly RMCE-targeted clones can render drug resistance thanks to a promoter on the incoming vector that restores a "trapped," promoter-less Neomycin resistance gene (Neo R ) present in the R26 genome of the docking cells (Figure 1 ) 10, 11 . This results in a very high targeting efficiency, often close to 100% 11, 12 . In conclusion, RMCE-based targeting is highly efficient and can be used for structure-functions studies; however, it requires a pre-engineered genomic locus.
Figure 1. Schematic Representation of RMCE-mediated
Targeting. RMCE allows for the exchange of DNA segments from an incoming targeting vector to a defined genomic locus if both harbor two heterospecific Frt sites (depicted by white and red triangles). In addition, the engineered genomic locus contains a promoterless and truncated neomycin-resistance (Neo R ) gene. By providing a promoter and start codon in the incoming DNA fragment, only correct recombination events restore neomycin resistance, resulting in high targeting efficiencies. Please click here to view a larger version of this figure.
Genome engineering in mESCs allows for the generation of RMCE-compatible mice. In 1981, two groups succeeded in capturing pluripotent cells from the inner cell mass (ICM) of blastocysts and in maintaining them in culture 13, 14 . mESCs are capable of self-renewal and differentiation into all types of embryonic and adult cells, including the germ-cell lineage. Therefore, gene targeting in mESCs enables reverse-genetic studies through the development of constitutive or conditional (using the Cre/LoxP system) KO mice. However, the classical way to isolate mouse ES cells is very inefficient. Several major improvements have greatly increased the success rate for deriving mESC lines, including the use of a defined serum-replacement (SR) medium 15 , alternating between mESC medium containing SR and fetal bovine serum (FBS) 16 , and the use of pharmacological compounds such as pluripotin or 2i 17 . Pluripotin, a small synthetic molecule, allows for the propagation of mESCs in an undifferentiated state in the absence of leukemia inhibitory factor (LIF) and mouse embryonic fibroblasts (MEFs) 18 . Finally, it has been shown that mESCs can be isolated with a very high efficiency (close to 100%) when an SR/FBS medium alternation protocol is combined with LIF and pluripotin 19, 20 . These protocols enable the efficient isolation of RMCE-compatible KO mESCs that can subsequently be used for structurefunction studies.
This paper describes a method that enables one to identify the key domains or residues within a protein that are responsible for specific cellular processes. To this end, a pipeline of advanced technologies that enable efficient mESC isolation, targeting vector assembly, and mESC targeting was created. As such, large panels with protein isoforms, domain mutants, and downstream effectors can be introduced in KO mESCs and can be evaluated for their ability to rescue the in vitro KO phenotype.
. Both RMCE-compatible mice were maintained on a mixed 129/C57BL6/Swiss background. NOTE: Crossing with heterozygous KO mice is advised to overcome embryonic lethality in homozygous KO mice. 2. Use PCR to select heterozygous KO mice containing an RMCE cassette in the R26 locus 12 .
3. Breed RMCE-compatible, heterozygous KO mice with heterozygous KO mice and isolate RMCE-compatible, homozygous KO blastocysts.
1. Set up time matings in the evening and check for copulation plugs the next morning. NOTE: Plugs are made of coagulated secretions from the coagulating and vesicular glands of the male. These plugs fill the vagina of the female and persist for 8 -24 h after breeding. Plugged females are considered to be carrying 0.5 dpc (days post coitum) embryos. 1. To check for plugs, lift the female by the base of her tail and by examine her vaginal opening for a whitish mass. Spread the lips of the vulva slightly with an angled probe when the plug is difficult to see. Separate plugged females from their male.
2. Collect blastocysts at 3.5 dpc. 1. Euthanize pregnant females by the approved method (e.g., cervical dislocation). Make a midventral incision and dissect the uterus and oviduct (still attached to each other) using fine scissor and forceps. 2. Bend a 26-gauge needle into a 45° angle. Attach a 1-mL syringe filled with M2 medium to this bent needle and use it to flush the blastocysts from the uterus into the lid of a 10-cm dish. 1. Insert the needle into the end of the uterus that is closest to the oviduct. Hold the needle in place with fine forceps while pushing the plunger; swelling of the uterus indicates a successful flushing.
3. Use a mouth pipette (with a diameter of 100 -200 µm) to collect all embryos and wash them twice in a drop of fresh M2 medium. Immediately after washing them, transfer the blastocysts to the culture plates (see below). NOTE: The dissection and handling of blastocysts of should be done in laminar air flow.
4. Isolate RMCE-compatible KO mESCs 1. Prepare a 12-well plate with mitomycin-C-treated DR4 MEFs (see the Table of Materials) one day before the blastocyst isolation. NOTE: These MEFs were isolated from Tg(DR4)1Jae/J mice that contain four drug-selectable genes and confer resistance to neomycin, puromycin, hygromycin, and 6-thioguanine 22 . 1. Coat all culture plates with 0.1% gelatin. Add 0.1% gelatin to the culture plates, incubate for 5 min at 37 °C in 5% CO 2 , and aspirate the gelatin solution. Seed one quarter of a vial of P2 MEFs in a 12-well plate and grow them in 2 mL of MEF medium (see Table 1 , the Table of Materials) to a confluent monolayer 19 . 2. Inactivate them with mitomycin-C (10 µg/mL) for 3 h and wash them twice with phosphate-buffered saline (PBS) 19 .
2. Using a mouth pipette, plate the blastocysts onto gelatinized 12-well plates (1 well/embryo), with the mitomycin-C-treated MEFs in SR-ES cell medium (2 mL/well) supplemented with either 2 µM pluripotin or with 2i (1 µM Erk inhibitor PD0325901 and 3 µM Gsk3 inhibitor CHIR99021). Incubate at 37 °C in 5% CO 2 . 3. Refresh the SR-ES cell medium (supplemented with pluripotin or 2i) every 2 -3 days. 4. Examine each blastocyst under a stereomicroscope at 4.0X magnification and check for hatching and attachment to the MEF layer.
NOTE: When blastocysts hatch, they lose the zona pellucida that encapsulates them. Wells with unattached blastocysts need to be refreshed using the mouth pipetting. 5. Pick individual ICM outgrowths (using a stereomicroscope) after 10 -12 days of culture using a P10 pipette with disposable tips.
Transfer the outgrowth in approximately 10 µL of medium to a V-shaped, 96-well plate containing 30 µL/well of PBS (at room temperature). 6. Add 50 µL of 0.25% trypsin to each well using a multichannel pipette and incubate for 3 min at 37 °C in 5% CO 2 . 7. Add 100 µL of FBS-containing mESC medium; dissociate the ICM outgrowths into single cells by pipetting 10-15 times; and transfer the dissociated cells to mitomycin-C-treated, 96-well MEF plates that were prepared one day before the ICM colonies are picked. 8. From this step onwards, omit pluripotin or 2i from the mESC medium. On the next day, change the medium from FBS-to SR-containing mESC medium (100 µL/well). 9. Expand the established mESC lines from 96-to 24-well format 19 .
1. Wash the cells with 200 µL of PBS, add 50 µL of trypsin, and incubate for 5 min at 37 °C in 5% CO. Add 100 µL of FBSbased mESC medium; dissociate by pipetting 10 -15 times using a multichannel pipette; and transfer the dissociated cells to mitomycin-C-treated, 24-well MEF plates. 2. Change to SR-based medium on the next day. Expand the mESCs in a similar fashion from 24-to 6-well format. Make 3 -4 freezings from a confluent 6-well plate To map the domains or amino acids within a protein that are important for specific cellular functions, one can now reintroduce, via RMCE, fulllength or mutant constructs in KO mESCs and test them for their ability to revert the KO phenotype. Targeting vectors for many different domain mutants and point mutants can be efficiently generated by recombinational cloning (Figure 3A) . Recombinational cloning is based on the recognition of specific attachment (Att) DNA sequences by the recombinase mix, which mediates an exchange of Att-flanked DNA fragments between different plasmids. The recombinational cloning system selects only correctly recombined vectors by switching between vectors that contain different antibiotic-resistance genes and by inserting a counter-selectable marker, the "control of cell death B" (ccdB) gene, into the destination vector ( Figure 3A) . We have generated over 25 Cre-excised pRMCE-DV1 targeting vectors with a near 100% efficiency (some examples are shown in Table 2 ).
Table 2. Overview of Targeting Vector Assembly and RMCE-mediated mESC Targeting.
Different rescue constructs embedded in a cre-excised pRMCE-DV1 targeting vector can easily be targeted to KO mESCs using RMCE ( Figure  3B) . We previously reported on the generation of 133 targeted mESC clones for 19 different rescue constructs that were introduced into the R26 locus of p120ctn KO mESCs via RMCE with an average efficiency of 93% 12 .
Here, we report on the targeting of additional constructs with similar high efficiencies, including a CAAX-tagged p120ctn 1A, epithelial-to-mesenchymal transition (EMT) inducers of the SNAI and ZEB family, and Ncadherin, in p120ctn KO mESCs ( Table 2 ). Once a panel of rescue mESCs is obtained, it needs to be screened for its ability to reverse the KO-induced phenotype. It was recently shown that p120ctn KO mESCs fail to differentiate into cystic EBs as a consequence of defective endoderm polarization 12 . Cystic EB morphology can be used as a phenotypic readout to screen different rescue constructs ( Figure 4A) . As proof of concept, we showed that R26-driven p120ctn isoform 1A (R_p120_1A) could rescue the p120ctn KO phenotype (Figure 4B, 4C ) 12 . In addition, this screen-identified E-cadherin, but not RhoA, is a crucial partner of p120ctn during endoderm specification (Figure 4B and C) 12 . The ease of introducing rescue constructs to p120ctn KO mESCs allowed us to test additional hypotheses. First, would E-cadherin-independent membrane anchoring of p120ctn enable cystic EB formation? To test this, we fused the K-Ras membrane-targeting motif (CAAX) to the carboxy terminus of p120ctn, introduced it via RMCE to p120ctn KO mESCs, and made EBs from them. However, this construct serves a dominant negative that does not allow binding and stabilization of E-cadherin ( Figure 4D) and, as a consequence, does not rescue the p120ctn KO phenotype (Figure 4C) . Second, are inducers of EMT involved? EMT is an essential developmental process that also occurs during mESC differentiation and is orchestrated by the SNAI and ZEB family of transcription factors, which directly repress various epithelial marker genes like E-cadherin 26, 27 . In line with these findings, the expression of EMT inducer ZEB2 was found in control EBs, but not in p120ctn-null EBs (Figure 4E) . Nonetheless, p120ctn KO mESCs with the ROSA26-based expression of EMT inducers ZEB1, ZEB2, or Snail failed to restore cystic EB formation (Figure 4C) . Third, can other classical cadherins, such as N-cadherin, functionally replace E-cadherin during endoderm specification? To address this, N-cadherin rescue lines were generated. Previously, it was shown that the ectopic expression of E-cadherin in p120ctn KO EBs partially rescued the formation of cystic EBs 12 . Interestingly, in a similar setup, forced N-cadherin expression failed to rescue (Figure 4C and F) , indicating that E-cadherin is the major cadherin subtype required for EB adhesion and cannot be replaced by N-cadherin. These abovementioned examples highlight the ease with which biological questions can be addressed by the system. To conclude, we report on a pipeline of robust technologies that combines a near-100% efficiency in mESC isolation with targeting vector assembly and mESC targeting. This pipeline enables us to unravel the versatility of proteins by means of structure-function studies in mESCs.
Discussion
Our mESC isolation method is user-friendly and does not require advanced skills or equipment, such as microsurgery of blastocysts. Thus, this technology is accessible to a large proportion of the scientific community. Anyone with basic cell culture experience can propagate ICM outgrowths and establish mESCs lines. However, the flushing and handling of blastocysts requires some practice. A mouth pipette is used to transfer blastocysts and consists of a micropipette, a micropipette holder, tubing, and an aspirator mouthpiece 28 . Micropipettes can be custommade by heating the finest part of a Pasteur pipette for a few seconds, removing the pipette from the flame, and pulling both ends. Select needles with a diameter slightly larger than a blastocyst (100 -200 µm). Needles can be reused after being washed with distilled water (3x) and EtOH (3x). In our experience, the efficiency of pluripotin-based mESC isolation is higher compared to 2i-based protocols 12 . However, the use of pluripotin at high concentrations has been shown to induce genomic instability 19 . RMCE-based R26-targeting in mESCs typically yields 20 -40 colonies after G418 selection. If more colonies are observed, this implies that the G418 concentration is not optimal and allows non-targeted mESCs to survive, affecting the overall targeting efficiency. Therefore, it is advised that, for each mESC line and for each new G418 batch, a kill curve is made to identify the lowest G418 concentration that kills all non-targeted mESCs. If no colonies are observed, this is indicative of an inefficient transfection. In that case, it is worthwhile to optimize the transfection procedure using reporter plasmids that allow the expression of EGFP or LacZ. If the transfection protocol works but still no colonies are observed, check the RMCE-compatible and cre-excised pRMCE-DV1 vector and the FLPe expression plasmid with RE digest and sequencing. It is advisable to make a big batch of parental mESCs and FLPe vector and to freeze several aliquots of them to reduce variation between experiments.
One drawback of this structure-function strategy is that the rescue constructs are not expressed from the endogenous locus, but rather from within the ROSA26 locus, with a ubiquitous, moderately active promoter. Compared to other technologies, where supraphysiological overexpression levels are often seen, this system enables physiological transgene expression, which is stable during in vitro differentiation experiments and across various cell lineages. It was observed that heterozygote, ROSA26-mediated transgene expression results in a p120ctn protein expression that was about half of the endogenous p120ctn levels of wildtype control mESCs but that was sufficient to rescue the observed p120ctn KO phenotypes 12 . Similarly, it was demonstrated previously that a heterozygote, ROSA26-mediated Zeb2 transgene expression level is sufficient to rescue the Zeb2 knockout phenotypes observed in vitro and in vivo in various cell lineages 29 . Another potential pitfall is the fact that genes that are indispensable for mESC self-renewal are not amenable for such structure-function studies. To exclude this, it is advised to characterize newly established KO mESCs for the following criteria: proliferation, colony morphology, and expression of stemness genes. It is also recommended to check the expression of the gene of interest, both in mESCs and in lineage-committed cells.
In addition to performing structure-function studies in constitutive KO mESCs, one could also take a conditional approach using the Cre/loxP system. The latter approach allows a lineage-specific KO without affecting the surrounding and supporting cells. In addition, conditional KO mESCs allow for the performance of structure-function studies if there is a phenotype in the constitutive KO mESCs. To generate RMCEcompatible, conditional-KO mESCs, homozygous floxed mice with a cell-type-specific Cre driver are bred with RMCE-compatible mice; mESC are isolated from their progeny. The advantage of this system is that the Cre recombinase is not expressed in mESCs and only becomes active when the mESCs are differentiated in the respective cell lineage. In RMCE-compatible, conditional-KO mESCs, Cre recombination will induce the simultaneous inactivation of the endogenous gene and the R26-driven expression of the rescue construct by using a conditional pRMCE-DV1 targeting vector (LMBP 08870) 11 .
In addition, the structure-function system allows for the study of mutations that are found in human disease and enables us to test the impact of these mutations on the functions of the protein. As an example, we have identified ZEB2 mutations in patients with myeloproliferative neoplasm, made targeting vectors containing these ZEB2 mutants, shuttled them to the R26-locus of Zeb2 KO mESCs via RMCE, and examined the effect of the mutations on the stability of the protein itself 30 . This technology gives a greater understanding of the biochemistry of such mutants in mESCs, as well in any given lineage, since mESCs are pluripotent.
In conclusion, this mESC-based structure-function approach relies on efficient mESC isolation and targeting technology and allows for the identification of important domains and functions of a given protein within a defined biological context. By sharing mice (frozen sperm is available upon request) and plasmids (distributed from BCCM/LMBP and Addgene), we want to open this technology to the entire scientific community.
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